Back to top
more

Abeona Therapeutics (ABEO)

(Real Time Quote from BATS)

$3.40 USD

3.40
5,168,412

-4.09 (-54.63%)

Updated Apr 23, 2024 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alkermes (ALKS) Receives FDA CRL in Relation to ALKS 3831

by Zacks Equity Research

Alkermes (ALKS) gets a CRL by the FDA for ALKS 3831 for the treatment of adults with schizophrenia and bipolar I disorder.

Kodiak (KOD) Closes Enrollment in Phase IIb/III Wet AMD Study

by Zacks Equity Research

Kodiak Sciences (KOD) completes recruitment in the pivotal phase IIb/III DAZZLE study, currently evaluating KSI-301 for the treatment of patients with wet age-related macular degeneration.

Encompass Health (EHC) Continues to Bolster Presence in Ohio

by Zacks Equity Research

Encompass Health (EHC) continues to expand in Ohio via inauguration of the inpatient rehabilitation hospital in order to offer improved health services in the state.

Centene (CNC) Marketplace Product Undergoes Technology Upgrade

by Zacks Equity Research

Centene's (CNC) Marketplace product - Ambetter undertakes technology improvements for benefiting members and new enrollees.

Denali Therapeutics (DNLI) Surges: Stock Moves 5.7% Higher

by Zacks Equity Research

Denali Therapeutics (DNLI) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Abeona Therapeutics (ABEO) Reports Q3 Loss

by Zacks Equity Research

Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of 38.46% and 0.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Abeona Restarts Enrollment in Connective Tissue Disorder Study

by Zacks Equity Research

Abeona (ABEO) restarts patient enrollment in phase III VIITAL study of EB-101 for the treatment of recessive dystrophic epidermolysis bullosa.

Here's Why Hold Strategy is Apt for Select Medical Stock

by Zacks Equity Research

Select Medical (SEM) is well poised to benefit from improved revenues and strong cash flows.

Encompass Health Tie-Up to Improve Healthcare in Knoxville

by Zacks Equity Research

Encompass Health (EHC) and Covenant Health intend to offer improved healthcare services in Knoxville through a joint venture.

Acadia Healthcare Ties Up for Improved Behavioral Services

by Zacks Equity Research

Acadia Healthcare (ACHC) partners with Covenant Health for offering improved mental health services in East Tennessee.

Humana Contract Renewal to Aid Medicaid Members in Kentucky

by Zacks Equity Research

Humana's (HUM) new agreement intends to efficiently serve Medicaid members of Kentucky, where it already boasts of a strong base.

Is Abeona Therapeutics (ABEO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ABEO) Outperforming Other Medical Stocks This Year?

Blueprint Medicines Gets CRL for Ayvakit in Fourth-Line Gist

by Zacks Equity Research

The FDA issues a CRL to Blueprint Medicines' (BPMC) NDA for Ayvakit to treat adults with unresectable/metastatic fourth-line GST.

Allogene Therapeutics (ALLO) in Focus: Stock Moves 6.6% Higher

by Zacks Equity Research

Allogene Therapeutics (ALLO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Agenus' (AGEN) IND for iNKT Therapy Gets FDA Acceptance

by Zacks Equity Research

The FDA clears Agenus' (AGEN) IND application for allogeneic iNKT therapy, agenT-797, which is being developed to treat cancer as well as the deadly COVID-19 pandemic.

AMAG Pharmaceuticals (AMAG) Reports Q1 Loss, Beats on Revenues

by Zacks Equity Research

AMAG Pharmaceuticals' (AMAG) loss narrows year over year while sales top estimates in the first quarter of 2020. The company scraps 2020 outlook due to the plaguing pandemic effect.

Axsome's (AXSM) Earnings Miss in Q1, Pipeline Progresses

by Zacks Equity Research

Axsome (AXSM) incurs a wider loss in the first quarter of 2020. However, the company is advancing well with the NDA for AXS-05 and AXS-07.

Pacira's (PCRX) Q1 Earnings Top Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Pacira (PCRX) beats on both earnings and revenues in the first quarter of 2020. The company temporarily suspends 2020 guidance in the wake of the COVID-19 pandemic.

ACADIA's (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

ACADIA's (ACAD) earnings and sales lag estimates in the first quarter of 2020. The company trims its 2020 revenue guidance due to the coronavirus impact. Stock declines in after-hours trading.

Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) beat on earnings and sales in the first quarter of 2020. The company lifts net sales guidance for the full year.

Moving Average Crossover Alert: Abeona Therapeutics

by Zacks Equity Research

Abeona Therapeutics is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front

Top Ranked Momentum Stocks to Buy for April 28th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 28th

Can Vertex (VRTX) Withstand the Coronavirus Impact on Q1 Earnings?

by Zacks Equity Research

On Vertex's (VRTX) first-quarter earnings call, investor focus will be on the sales uptake of its newly-launched CF drug, Trikafta.

Is a Beat in Store for Abeona (ABEO) This Earnings Season?

by Zacks Equity Research

Abeona's (ABEO) operating expenses are expected to have increased in the first quarter driven by clinical studies on its lead gene therapy candidate.

Celldex (CLDX) Soars: Stock Adds 10% in Session

by Zacks Equity Research

Celldex (CLDX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.